



## **Akebia Therapeutics to Present at Upcoming Investor Conferences**

March 21, 2018

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 21, 2018-- [Akebia Therapeutics](http://www.akebia.com), Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced its participation in the following upcoming investor conferences:

- Needham & Company's 17<sup>th</sup> Annual Healthcare Conference on Tuesday, March 27, 2018, at 1:30 p.m. Eastern Time, at the Westin Grand Central Hotel in New York, NY; and
- The H.C. Wainwright Global Life Sciences Conference on Monday, April 9, 2018, at 11:55 a.m. Central European Time, at the Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco.

A live webcast of the presentations will be available on the company's website at [www.akebia.com](http://www.akebia.com). To access the webcasts, please log onto the Akebia website at least 15 minutes prior to the webcast to ensure adequate time for any software downloads that may be required. A replay of the webcasts will be available on Akebia's website following the conferences.

### **About Akebia Therapeutics**

Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor biology. For more information, please visit our website at [www.akebia.com](http://www.akebia.com), which does not form a part of this release.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20180321005145/en/>

Source: Akebia Therapeutics, Inc.

### **Akebia Therapeutics Contact:**

John Garabo, 617-844-6130  
Director, Corporate Communications  
[jgarabo@akebia.com](mailto:jgarabo@akebia.com)